Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 228,713	$ 173,016
Marketable securities, at fair value	67,546	0
Accounts receivable, net	106,843	94,242
Inventories	29,526	14,405
Prepaid assets	11,547	6,327
Other current assets	4,555	2,748
Total current assets	448,730	290,738
Property and equipment (net of accumulated depreciation of $92,895 and $68,809, respectively)	85,873	64,188
Operating lease right-of-use assets	45,786	26,492
Intangible assets, net	120,653	126,640
Goodwill	211,083	198,601
Restricted cash	21,919	0
Prepaid lease asset	20,229	0
Investment in non-consolidated affiliate	29,555	0
Other assets	4,503	2,847
Total non-current assets	539,601	418,768
Total assets	988,331	709,506
Current liabilities
Accounts payable	24,965	19,568
Accrued compensation	24,727	21,365
Accrued expenses and other liabilities	11,654	7,548
Current portion of equipment financing obligations	2,841	5,432
Current portion of operating lease liabilities	4,967	3,381
Current portion of term loan	0	5,000
Current pharma contract liabilities	4,029	1,610
Total current liabilities	73,183	63,904
Long-term liabilities
Convertible senior notes, net	168,120	0
Equipment financing obligations	967	3,199
Operating lease liabilities	42,296	24,034
Term loan, net	0	91,829
Deferred income tax liabilities, net	5,415	15,566
Other long-term liabilities	4,056	3,566
Total long-term liabilities	220,854	138,194
Total liabilities	294,037	202,098
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 112,075,474 and 104,781,236 shares issued and outstanding, respectively)	112	105
Additional paid-in capital	701,357	520,278
Accumulated other comprehensive loss	10	(1,618)
Accumulated deficit	(7,185)	(11,357)
Total stockholders’ equity	694,294	507,408
Total liabilities and stockholders’ equity	$ 988,331	$ 709,506